Latest On Fresenius SE & Co. KGaA (FSNUF):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2023-05-18 05:57 EST | Dividend | A dividend of $0.92 has been announced on Feb 27, 2023. It will be paid May 23, 2023 with an ex-dividend date of May 18, 2023. | Neutral |  |
| 2023-02-22 20:00 EST | News | Fresenius SE & Co. KGaA GAAP EPS of €0.79, revenue of €10.64B | N/A | |
| 2023-02-21 18:29 EST | News | Fresenius evaluating selling Quironsalud for as much as €7B - report | N/A | |
| 2022-11-01 18:32 EST | News | Fresenius SE & Co. KGaA GAAP EPS of €0.57, revenue of €10.45B beats by €270M | N/A | |
| 2022-10-19 17:39 EST | News | Fresenius Medical gains after report of activist Elliott stake in Fresenius SE | N/A | |
| 2022-09-25 02:33 EST | News | Fresenius - No One Likes A Contrarian During A Downturn | N/A | |
| 2022-05-16 05:56 EST | Dividend | A dividend of $0.92 has been announced on Feb 22, 2022. It will be paid Jun 13, 2022 with an ex-dividend date of May 16, 2022. | Neutral | |
| 2022-05-04 16:15 EST | News | Fresenius SE & Co. KGaA GAAP EPS of €0.83, revenue of €9.72B misses by €230M | N/A | |
| 2022-02-22 13:56 EST | News | Fresenius SE Non-GAAP EPS of €3.35, revenue of €37.52B | N/A | |
| 2021-11-03 03:22 EST | News | Fresenius SE & Co. KGaA reports Q3 results | N/A | |
| 2021-07-30 05:22 EST | News | Fresenius SE & Co. KGaA beats on revenue | N/A | |
| 2021-05-25 06:00 EST | Dividend | A dividend of $0.88 has been announced on Feb 23, 2021. It will be paid May 27, 2021 with an ex-dividend date of May 25, 2021. | Neutral | |
| 2021-03-18 06:18 EST | Analyst Rating | The Analyst Target Price has decreased from $13.77 to $13.75. | Sell | |
| 2021-03-17 14:26 EST | Analyst Rating | The Analyst Target Price has decreased from $13.8 to $13.77. | Sell | |
| 2021-03-14 01:09 EST | Analyst Rating | The Analyst Target Price has decreased from $13.84 to $13.8. | Sell | |
| 2021-03-13 04:56 EST | Analyst Rating | The Analyst Target Price has increased from $13.77 to $13.84. | Neutral | |
| 2021-03-12 05:12 EST | Analyst Rating | The Analyst Target Price has increased from $13.74 to $13.77. | Neutral | |
| 2021-03-11 01:18 EST | Analyst Rating | The Analyst Target Price has increased from $13.69 to $13.74. | Neutral | |
| 2021-03-10 05:23 EST | Analyst Rating | The Analyst Target Price has decreased from $13.77 to $13.69. | Sell | |
| 2021-03-09 01:08 EST | Analyst Rating | The Analyst Target Price has increased from $13.75 to $13.77. | Neutral | |
| 2021-03-07 13:05 EST | Financials | Company financials have been released. | Neutral | |
| 2021-03-07 01:02 EST | Analyst Rating | The Analyst Target Price has decreased from $13.82 to $13.75. | Sell | |
| 2021-03-06 01:14 EST | Analyst Rating | The Analyst Target Price has decreased from $13.92 to $13.82. | Sell | |
| 2021-03-05 12:49 EST | Analyst Rating | The Analyst Target Price has decreased from $13.96 to $13.92. | Sell | |
| 2021-03-04 01:20 EST | Analyst Rating | The Analyst Target Price has increased from $13.92 to $13.96. | Neutral | |
| 2021-03-03 01:45 EST | Analyst Rating | The Analyst Target Price has increased from $11.55 to $13.92. | Neutral | |
| 2021-02-27 13:03 EST | Financials | Company financials have been released. | Neutral | |
| 2021-02-24 05:20 EST | Earnings Estimate | An EPS average of $3.63 is estimated for the 2022 year. | Buy | |
| 2021-02-22 00:54 EST | Analyst Rating | The Analyst Target Price has decreased from $13.99 to $11.55. | Sell | |
| 2021-02-21 01:05 EST | Analyst Rating | The Analyst Target Price has increased from $13.97 to $13.99. | Neutral | |
| 2021-02-20 01:07 EST | Analyst Rating | The Analyst Target Price has increased from $13.91 to $13.97. | Neutral | |
| 2021-02-19 05:20 EST | Analyst Rating | The Analyst Target Price has decreased from $13.97 to $13.91. | Sell | |
| 2021-02-18 05:20 EST | Analyst Rating | The Analyst Target Price has decreased from $14.01 to $13.97. | Sell | |
| 2021-02-17 01:08 EST | Analyst Rating | The Analyst Target Price has increased from $11.55 to $14.01. | Neutral | |
| 2021-02-16 01:12 EST | Analyst Rating | The Analyst Target Price has decreased from $14 to $11.55. | Sell | |
| 2021-02-14 01:03 EST | Analyst Rating | The Analyst Target Price has decreased from $14.01 to $14. | Sell | |
| 2021-02-13 01:18 EST | Analyst Rating | The Analyst Target Price has increased from $14 to $14.01. | Neutral | |
| 2021-02-12 12:47 EST | Analyst Rating | The Analyst Target Price has decreased from $14.09 to $14. | Sell | |
| 2021-02-11 01:10 EST | Analyst Rating | The Analyst Target Price has increased from $11.63 to $14.09. | Neutral | |
| 2021-02-10 08:54 EST | Analyst Rating | The Analyst Target Price has decreased from $14 to $11.63. | Sell | |
| 2021-02-07 01:04 EST | Analyst Rating | The Analyst Target Price has increased from $13.92 to $14. | Neutral | |
| 2021-02-06 01:18 EST | Analyst Rating | The Analyst Target Price has decreased from $14 to $13.92. | Sell | |
| 2021-02-05 12:48 EST | Analyst Rating | The Analyst Target Price has increased from $13.91 to $14. | Neutral | |
| 2021-02-05 01:21 EST | Analyst Rating | The Analyst Target Price has decreased from $13.92 to $13.91. | Sell | |
| 2021-02-04 13:13 EST | Analyst Rating | The Analyst Target Price has decreased from $13.95 to $13.92. | Sell | |
| 2021-02-03 01:06 EST | Analyst Rating | The Analyst Target Price has increased from $11.56 to $13.95. | Neutral | |
| 2021-02-02 13:24 EST | Analyst Rating | The Analyst Target Price has decreased from $14.01 to $11.56. | Sell | |
| 2021-02-02 05:29 EST | Analyst Rating | The Analyst Target Price has increased from $11.56 to $14.01. | Neutral | |
| 2021-01-30 13:02 EST | Analyst Rating | The Analyst Target Price has decreased from $14.01 to $11.56. | Sell | |
| 2021-01-30 01:08 EST | Analyst Rating | The Analyst Target Price has increased from $11.56 to $14.01. | Neutral | |
About Fresenius SE & Co. KGaA (FSNUF):
Fresenius SE & Co. KGaA, a health care group, provides products and services for dialysis, hospitals, and outpatient medical care worldwide. The company operates through four segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. The Fresenius Medical Care segment offers products and services for patients with chronic kidney failure. This segment offers dialyzers, hemodialysis machines, and related disposable products, as well as dialysis-related services. The Fresenius Kabi segment specializes in the therapy and care of chronically and critically ill patients. This segment offers IV drugs, including intravenously administered generic anesthetics, analgesics, anti-infectives, and drugs for the treatment of oncological and other critical diseases; parenteral and enteral nutrition products; infusion solutions and blood volume substitutes for infusion therapy; infusion and nutrition pumps, as well as consumables; and products that are used in the collection and processing of blood components, as well as in transfusion medicine and cell therapy. As of December 31, 2019, this segment operated 86 hospitals, approximately 125 outpatient clinics, and 8 prevention centers. The Fresenius Vamed segment manages projects and provides services for hospitals and other health care facilities. This segment offers project development, planning, and turnkey construction services, as well as maintenance, technical management, and operational management services. Fresenius SE & Co. KGaA has a strategic partnership with Humacyte Inc. The company was formerly known as Fresenius SE and changed its name to Fresenius SE & Co. KGaA in January 2011. Fresenius SE & Co. KGaA was founded in 1912 and is headquartered in Bad Homburg vor der Höhe, Germany.
General
- Name Fresenius SE & Co. KGaA
- Symbol FSNUF
- Type Common Stock
- Exchange PINK
- Currency USD
- Country USA
- SectorHealthcare
- IndustryMedical Care Facilities
- Full Time Employees 311,269
- Last Split Factor3:1
- Last Split Date2014-08-04
- Fiscal Year EndDecember
- Web URLhttp://www.fresenius.com
Valuation
- Trailing PE 10.24
- Forward PE 11.17
- Price/Sales (Trailing 12 Mt.) 0.56
- Price/Book (Most Recent Quarter) 1.18
- Enterprise Value Revenue 1.45
- Enterprise Value EBITDA 7.2
Financials
- Most Recent Quarter 2020-12-31
- Current Year EPS Estimate $3.84
- Next Year EPS Estimate $4.32
- Profit Margin 5%
- Return on Assets 4%
- Return on Equity 11%
- Earnings Per Share $4.22
- Revenue Per Share $0
- Gross Profit 10.32 billion
- Quarterly Earnings Growth -0.1%
ESG Rating
Highlights
- Market Capitalization 23.84 billion
- PEG Ratio 1.94
- Analyst Target Price $13.75
- Book Value Per Share $31.04
Share Statistics
- Shares Outstanding 446.56 million
- Shares Float 407.03 million
- % Held by Insiders 2699%
- % Held by Institutions 37.74%
Technicals
- Beta 1.21
- 52 Week High $51.65
- 52 Week Low $31.44
- 50 Day Moving Average 44.46
- 200 Day Moving Average 44.74
Dividends
- Forward Annual Dividend Rate $1.07
- Forward Annual Dividend Yield 2.48%
- Payout Ratio 26%
- Dividend Date N/A
- ExDividend Date 2021-05-25
- Dividend Per Share $0.87
- Dividend Yield 0%
Fresenius SE & Co. KGaA (FSNUF) Dividend Calendar:
Fresenius SE & Co. KGaA pays out 26% of its earnings out as a dividend.
| Ex-Dividend Date | Payment Date | Record Date | Declared Date | Amount |
|---|
Fresenius SE & Co. KGaA (FSNUF) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
| Quarter Date | Report Date | Actual Revenue | Reported EPS | EPS Estimate | Deviation from Estimate |
|---|---|---|---|---|---|
| 2020-12-31 | 2020-12-31 | $N/A | $1.05 | $1.04 | 0.96% |
| 2020-09-30 | 2020-12-31 | $N/A | $1.08 | $0.74 | 46.28% |
| 2020-06-30 | 2020-09-30 | $N/A | $0.90 | $0.72 | 25.4% |
| 2020-03-31 | 2020-06-30 | $N/A | $0.83 | $0.74 | 12.38% |
| 2019-12-31 | 2020-03-31 | $10.44 billion | $0.90 | $0.91 | -0.69% |
| 2019-09-30 | 2019-12-31 | $9.64 billion | $1.04 | $0.77 | 34.62% |
| 2019-06-30 | 2019-09-30 | $9.95 billion | $0.86 | $0.82 | 5.01% |
| 2019-03-31 | 2019-06-30 | $9.53 billion | $0.97 | $0.81 | 19.33% |
| 2018-12-31 | 2019-03-31 | $10.13 billion | $0.91 | $0.89 | 2.09% |
| 2018-09-30 | 2018-12-31 | $9.48 billion | $1.05 | $0.80 | 31.49% |
| 2018-06-30 | 2018-09-30 | $9.76 billion | $0.87 | $0.84 | 3.65% |
| 2018-03-31 | 2018-06-30 | $9.99 billion | $1.37 | $0.78 | 75.15% |
| 2017-12-31 | 2018-03-31 | $10.44 billion | $0.97 | $0.92 | 5.77% |
| 2017-09-30 | 2017-12-31 | $9.73 billion | $1.10 | $0.75 | 46.61% |
| 2017-06-30 | 2017-09-30 | $9.75 billion | $0.84 | $0.80 | 4.89% |
| 2017-03-31 | 2017-06-30 | $8.94 billion | $0.93 | $0.78 | 18.62% |
| 2016-12-31 | 2017-03-31 | $7.1 billion | $0.87 | $0.75 | 16.65% |
| 2016-09-30 | 2016-12-31 | $8.43 billion | $0.85 | $0.73 | 16.29% |
| 2016-06-30 | 2016-09-30 | $7.57 billion | $0.78 | $0.70 | 10.73% |
| 2016-03-31 | 2016-06-30 | $7.99 billion | $0.77 | $0.64 | 19.73% |
| 2015-12-31 | 2016-03-31 | $0.74 | $0.74 | 0.04% | |
| 2015-09-30 | 2015-12-31 | $0.71 | $0.63 | 13.46% | |
| 2015-06-30 | 2015-09-30 | $0.73 | $0.59 | 22.95% | |
| 2015-03-31 | 2015-06-30 | $0.66 | $0.44 | 49.36% | |
| 2014-12-31 | 2015-03-31 | $0.62 | $0.58 | 7.43% | |
| 2014-09-30 | 2014-12-31 | $0.57 | $0.85 | -33.47% | |
| 2014-06-30 | 2014-09-30 | $0.64 | $1.49 | -56.8% | |
| 2014-03-31 | 2014-06-30 | $0.71 | $1.30 | -45.24% | |
| 2013-12-31 | 2014-03-31 | $0.63 | $2.40 | -73.6% | |
| 2013-09-30 | 2013-12-31 | $0.73 | $0.00 | ||
| 2013-06-30 | 2013-09-30 | $0.66 | $0.00 | ||
| 2013-03-31 | 2013-06-30 | $0.58 | $0.00 | ||
| 2012-12-31 | 2013-03-31 | $0.52 | $0.00 | ||
| 2012-09-30 | 2012-12-31 | $0.60 | $0.00 | ||
| 2012-06-30 | 2012-09-30 | $0.58 | $0.00 | ||
| 2012-03-31 | 2012-06-30 | $0.51 | $0.00 | ||
| 2011-12-31 | 2012-03-31 | $0.62 | $0.00 | ||
| 2011-09-30 | 2011-12-31 | $0.54 | $0.00 | ||
| 2011-06-30 | 2011-09-30 | $0.62 | $0.00 | ||
| 2011-03-31 | 2011-06-30 | $0.38 | $0.00 | ||
| 2010-12-31 | 2011-03-31 | $0.37 | $0.00 | ||
| 2010-09-30 | 2010-12-31 | $0.51 | $0.00 | ||
| 2010-06-30 | 2010-06-30 | $0.40 | |||
| 2010-03-31 | 2010-03-31 | $0.25 | |||
| 2009-12-31 | 2009-12-31 | $0.47 | |||
| 2009-09-30 | 2009-09-30 | $0.19 | |||
| 2009-06-30 | 2009-06-30 | $0.31 | |||
| 2009-03-31 | 2009-03-31 | $0.44 | |||
| 2008-09-30 | 2008-09-30 | $0.35 | |||
| 2008-06-30 | 2008-06-30 | $0.37 | |||
| 2008-03-31 | 2008-03-31 | $0.30 | |||
| 2007-12-31 | 2007-12-31 | $0.33 | |||
| 2007-09-30 | 2007-09-30 | $0.30 | |||
| 2007-06-30 | 2007-06-30 | $0.30 | |||
| 2007-03-31 | 2007-03-31 | $0.28 | |||
| 2006-12-31 | 2006-12-31 | $0.28 | |||
| 2006-09-30 | 2006-09-30 | $0.50 |
Fresenius SE & Co. KGaA (FSNUF) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date |
|---|
| Research Development |
| Income Before Tax |
| Selling General Administrative |
| Gross Profit |
| Ebit |
| Operating Income |
| Income Tax Expense |
| Total Revenue |
| Cost of Revenue |
| Total Other Income Expense Net |
| Net Income From Continuing Operations |
| Net Income Applicable to Common Shares |
Cash Flow:
| Date |
|---|
| Investments |
| Change to Liabilities |
| Total Cash Flow from Investing Activities |
| Net Borrowings |
| Total Cash Flow from Financial Activities |
| Change to Operating Activities |
| Change in Cash |
| Total Cash from Operating Activities |
| Depreciation |
| Other Cash Flow from Investing Activities |
| Change to Inventory |
| Change to Account Receivables |
| Other Cash Flow from Financing Activities |
| Change to Net Income |
| Capital Expenditures |
Balance Sheet:
| Date |
|---|
| Total Liabailities |
| Total Stockholder Equity |
| Other Current Liabilities |
| Total Assets |
| Common Stock |
| Other Current Assets |
| Retained Earnings |
| Other Liabilities |
| Other Assets |
| Cash |
| Total Current Liabilities |
| Other Stockholder Equity |
| Property, Plant & Equipment |
| Total Current Assets |
| Long Term Investments |
| Net Tangible Assets |
| Short Term Investments |
| Long Term Debt |
| Inventory |
| Accounts Payable |
Fresenius SE & Co. KGaA (FSNUF) Chart:
Fresenius SE & Co. KGaA (FSNUF) News:
Below you will find a list of latest news for Fresenius SE & Co. KGaA (FSNUF) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
Fresenius SE & Co. KGaA (FSNUF) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
| Expiration Date | Strike | Last Price | Type | Volume | Open Interest | Implied Volatility | In The Money | Change | Change Percent |
|---|
Fresenius SE & Co. KGaA (FSNUF) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | Form Name | Link |
|---|